LEADER 02889nam  2200697 a 450 
001 9910966313903321
005 20240313192123.0
010   $a9781118682180
010   $a1118682181
010   $a9781299468832
010   $a1299468837
010   $a9781118682203
010   $a1118682203
035   $a(CKB)2670000000342126
035   $a(EBL)1165087
035   $a(OCoLC)836400729
035   $a(SSID)ssj0000856518
035   $a(PQKBManifestationID)12382870
035   $a(PQKBTitleCode)TC0000856518
035   $a(PQKBWorkID)10807891
035   $a(PQKB)10565313
035   $a(MiAaPQ)EBC1165087
035   $a(Au-PeEL)EBL1165087
035   $a(CaPaEBR)ebr10684967
035   $a(CaONFJC)MIL478133
035   $a(Perlego)1002802
035   $a(EXLCZ)992670000000342126
100   $a20110124d2011      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aNew mechanisms in glucose control /$fAnthony H. Barnett, Jenny Grice
205   $a1st ed.
210   $aChichester, West Sussex $cWiley-Blackwell$d2011
215   $a1 online resource (74 p.)
300   $aDescription based upon print version of record.
311 08$a9781118682197 
311 08$a111868219X 
311 08$a9781444334616 
311 08$a1444334611 
320   $aIncludes bibliographical references and index.
327   $aEpidemiology and pathogenesis of type 2 diabetes -- Overview of current diabetes management -- The incretin system -- The incretin mimetics -- Dipeptidyl peptidase-4 inhibitors -- Sodium-glucose cotransporter-2 inhibitors -- Pipeline diabetes therapies -- Bariatric surgery for the treatment of type 2 diabetes -- Organization of diabetes care.
330   $aNew Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabete
606   $aType 2 diabetes
606   $aHypoglycemic agents
606   $aObesity$xSurgery
615  0$aType 2 diabetes.
615  0$aHypoglycemic agents.
615  0$aObesity$xSurgery.
676   $a616.4/624
700   $aBarnett$b A. H$g(Anthony H.),$f1951-$01621466
701   $aGrice$b Jenny$01814921
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910966313903321
996   $aNew mechanisms in glucose control$94369143
997   $aUNINA

LEADER 00748nam  2200253la 450 
001 9910481097303321
005 20221102154902.0
035   $a(UK-CbPIL)2090320301
035   $a(CKB)5500000000083371
035   $a(EXLCZ)995500000000083371
100   $a20221102d1494      uy         |
101 0 $aita
135   $aurcn||||a|bb|
200 10$aFrutti della lingua
210   $aFlorence $cBartolommeo di Libri, fl. 1482-1511$d1494
215   $aOnline resource (v.)
300   $aReproduction of original in Biblioteca Nazionale Centrale di Firenze.
700   $aCavalca$b Domenico$f1342.$0186836
801  0$bUk-CbPIL
801  1$bUk-CbPIL
906   $aBOOK
912   $a9910481097303321
996   $aFrutti della lingua$91962763
997   $aUNINA